Oxidative lipid, protein, and DNA damage as oxidative stress markers in vascular complications of diabetes mellitus
Type 2 diabetes mellitus (DM) and its complications are frequently seen today, and with an increasing incidence. Increased oxidative stress is a widely accepted participant in the development and progression of diabetes and its complications. Excessively high levels of free radicals cause damage to cellular proteins, membrane lipids and nucleic acids, and eventually cell death [1] .
N ε -(hexanoyl)lysine (HEL), an early byproduct of lipid peroxidation, is formed from a lipid hydroperoxide and a lysine residue. HEL is considered to be one of the stable oxidative stress markers for lipid peroxide and protein modi cation [2] . An important role for oxidative stress in the increased HEL seen in diabetes is suggested by experimental and clinical studies [3, 4] .
Recently, a new marker of protein oxidation, advanced oxidation protein products (AOPP), has begun to attract the attention of various investigators [5] [6] [7] [8] . AOPP are proteins, predominantly albumin and its aggregates, which have been damaged by oxidative stress [9] .
Reactive oxygen species (ROS) can cause strand breaks in DNA and base modi cations, including oxidation of guanine residues to 8-hydroxy-2'deoxyguanosine (8-OHdG) -an oxidized nucleoside of DNA that is the most frequently detected and studied DNA lesion [10] . In recent years, several clinical studies have analyzed levels of 8-OHdG in human organs, leukocyte DNA and urine in relation to oxidative stress and diabetes mellitus [11] [12] [13] .
8-iso-prostaglandin F2α, or 8-epi-prostaglandin F2α, was renamed 15-F2t-IsoP [14] . Among the isoprostanes, the 15-F2t-IsoP has been shown to be both stable and biologically active, and it is produced in abundance during oxidative stress [15] . F2-isoprostanes may transduce the e ects of the oxidant stress associated with complex metabolic disorders into specialized forms of cellular activation. In particular, the lowgrade in ammatory state, characterizing metabolic disorders such as obesity, hypercholesterolemia, type 2 diabetes mellitus, and homozygous homocystinuria, may be the primary trigger of thromboxane-dependent platelet activation; mediated, at least in part, through enhanced lipid peroxidation [16] .
Paraoxonase (PON1) is associated with high-density lipoprotein (HDL). PON1prevents lipid oxidation: not only of LDL, but also of HDL itself [17] . is protection is probably related to the PON1-hydrolysing activity of some activated phospholipids [18] and/or lipid peroxide [19] products. Human PON1 (aryldialkylphosphatase, EC 3.1.8.1) is a 43 kDa esterase associated with apolipoprotein A1 (apoA-I) and clusterin (apolipoprotein J) in HDL. PON1 was shown to possess a peroxidase-like activity, which can contribute to its protective e ect against lipoprotein oxidation, as well as a homocysteinethiolactonase activity, which may be linked with its antiatherogenic properties [19, 20] .
In this study, we examine the role that oxidative stress plays in DM and its complications by measuring products of oxidative damage in the plasma: 8-OHdG, as a marker of oxidative DNA damage, HEL and 15-F2t-IsoP as products of lipooxidative damage and AOPP as markers of protein damage were studied.
Materials and Methods
e study included 69 type 2 diabetic patients; 20 of them without any of the vascular complications o en associated with type 2 diabetes mellitus (DM), 37 patients had microvascular complications either retinopathy, nephropathy, or neuropathy, four patients had macrovascular complications such as coronary artery disease, eight patients had mixed micro-and microvascular complications, as well as 20 healthy age-matched volunteers. All patients were clinically stable without any acute or chronic infection. Patients attending outpatient internal medicine clinics of Istanbul Education and Research who presented with febrile illness, diabetic ketoacidosis, or renal failure and those who were su ering from chronic diseases were excluded from the study. e patients did not receive any medications, including statins. Diabetic patients were given a diabetic diet. While dietary guidelines from the American Diabetes Association (ADA) were used to frame nutrition recommendations, additional content was adapted from the Turkey Diabetes Mellitus Association (TDMA) guidelines. A total of seven subjects were treated with insulin therapy (a er failure of oral hypoglycemic agents), 57 subjects with oral hypoglycemic agents (sulfonylureas or sulfonylureas plus biguanides) and ve with the combination of insulin and oral hypoglycemic agents. All subjects were non-smokers. Members of the control group were selected from the hospital sta without personal or family history of either diabetes or dyslipidemia and with normal thyroid, hepatic and renal functions. Neither DM patients nor healthy controls have received vitamin or mineral supplements. Two-hour glucose load was used to rule out impaired glucose regulation in healthy controls. Diabetes mellitus and impaired glucose tolerance (IGT) were diagnosed according to the 1998 WHO criteria [21] . Control groups were not taking any drugs known to a ect carbohydrate or lipid metabolism. Among the diabetic patients, 20 were free from any evidence of vascular complications while 49 diabetics had various kinds of vascular complications. Demographic (gender, age) and anthropometric data (weight, height, waist circumference), medical history (duration of disease, genetic background) and type of treatTabak et al. Diabetes mellitus and oxidative stress ment were recorded. e study was approved by the Ethical Committee on human research of Istanbul Education and Research Hospital. Written informed consent was obtained from all subjects.
Blood was drawn a er 12 -14 hours of fasting in the morning. Serum and plasma were obtained a er at least 30 minutes of clotting by centrifugation at 2500xg for 15 minutes. Serum samples were removed and used directly for measurements of routine parameters. Other serum and plasma samples were stored at -80ºC until use. All icteric or haemolytic blood samples were discarded. All reagents were analytical grade and purchased from Sigma Chemical Co (St. Louis, USA) and Merck (Darmstadt, Germany).
Routine parameters were determined on the Olympus AU 800 analyzer by enzymatic methods using commercial kits (Roche Diagnostics, GmbH, Mannheim, Germnay). Plasma insulin was measured by radioimmunoassay using a commercial kit (DSL-1600, USA). Homeostatic model assessment (HOMA) is a method for assessing beta cell function and insulin resistance (HOMA-IR) from basal (fasting) glucose and insulin. HOMA-IR was calculated by the formula [fasting glucose (mmol/L) x fasting insulin (μU/ml)] / 22.5.
Serum HEL levels were determined by ELISA using a commercial kit (Northwest Life Science Specialties, Vancouver, USA). HEL studies were performed using a competitive immunoassay kit according to the manufacturer's directions. e coe cients of intra-and interassay variations for HEL assay were 6.9% (n = 10) and 7.5% (n = 10), respectively. Serum 15-F2t-IsoP levels were determined by ELISA using a commercial kit (Northwest Life Science Specialties, Vancouver, USA). Serum 15-F2t-IsoP was measured using a competitive immunoassay kit according to the manufacturer's directions. e coe cients of intra-and interassay variations for 15-F2t-IsoP assay were 6.7% (n = 10) and 7.3% (n = 10), respectively.
e plasma 8-OHdG levels were determined using an enzyme linked immunosorbent assay detection kit (Northwest Life Science Specialties, Vancouver, USA). Plasma 8-OHdG was measured using a competitive immunoassay kit according to the manufacturer's directions. e coe cients of intra-and interassay variations for 8-OHdG assay were 6.4% (n = 10) and 7.0% (n = 10), respectively. Spectrophotometric determination of AOPP levels was performed by a kit according to the manufacturer's directions (Immundiagnostik, Bensheim, Germany). e coe cients of intra-and interassay variations for AOPP assay were 4.3% (n = 10) and 6.2% (n = 10), respectively. Plasma PON1 activity was assayed using synthetic paraoxon (diethyl--nitrophenyl phosphate) as substrate. PON1 activity was determined by measuring the initial rate of substrate hydrolysis to -nitrophenol, the absorbance of which was monitored at 412 nm in the assay mixture containing 2.0 mM paraoxon, 2.0 mM CaCl2 and 20 μl of plasma in 100 mM TrisHCl bu er (pH 8.0). e blank sample containing incubation mixture without plasma was run simultaneously to correct for spontaneous substrate breakdown. Enzymatic activity was calculated from the molar extinction coe cient 18.290 M -1 cm -1 and is expressed as units per milliliter. One unit of PON1 activity is de ned as 1 nmol of 4-nitrophenol formed per minute under the above assay conditions [22] . e intra-assay and inter-assay coe cients of variation were 6.8% (n = 25) and 3.3% (n = 25), respectively. Statistical analyses were carried out by using SPSS 11 package. Data are presented as the mean ± standard deviation (SD). Mann-Whitney U and Kruskal Wallis were used in comparison of groups. Correlations between changes in variables were tested using Pearson's correlation. P< 0.05 was considered statistically signi cant.
Results
Demographic and biochemical values of diabetic patients and control group are shown in Table 1 . ere was no di erence in age between the groups. Blood lipid levels, including LDLcholesterol, HDL-cholesterol and triglycerides, were not signi cantly di erent between the groups. BMI, glucose, HbA1c, microalbuminuria, HOMA-IR, brinogen, homocysteine and N-terminal-pro-brain-type natriuretic peptide (NT-proBNP) levels were signi cantly higher in patients with DM in comTabak et al. Diabetes mellitus and oxidative stress parison with the control group. ere were no di erences in other parameters between the groups.
Oxidative stress parameters of control and patient groups were shown in Table 2 . AOPP and 15-F2t-IsoP levels were signi cantly higher in diabetic group in comparison with the control group (p=0.001 and p=0.003, respectively). On the other hand, PON 1 was signi cantly lower in the diabetic group in comparison with the control group (p=0.001). ere were no signi cant di erences in HEL and 8-OHdG levels between the groups.
Demographic characteristics and clinical features of patients with and without complications are shown in Table 3 . Duration of diabetes was signi cantly longer in diabetics with complications (p=0.01). Similarly, fasting plasma glucose and HbA1c were signi cantly higher in diabetics with complications (p=0.001 and p=0.01, respectively).
Oxidative stress parameters of patients with and without complications are shown in Table 4 . AOPP and 8-OHdG were signi cantly higher in the group with complications (p=0.001 and p=0.001, respectively); however, PON 1 was signi cantly lower in the group with complications (0.01). ere was no signi cant di erence in HEL and 15-F2t-IsoP levels between the groups.
As shown in Fig. 1, 15 -F2t-IsoP levels were signi cantly positively correlated with fasting glucose (P<0.003, r = 0.36) in all patients, but no correlation was found between oxidative markers and other clinical parameters. Pearson's correlation coe cients between 8-OHdG and HEL and AOPP in all patients are shown in Fig. 2 
Discussion
Hyperglycemia is a major factor in the development of diabetic complications although the mechanisms by which increased glucose levels contribute to these changes have not been fully elucidated. Numerous studies have demonstrated oxidative stress, mediated mainly by hyperglycemia-induced generation of free radicals, but there is controversy about which of these is the most reliable and suitable marker for clinical practice. is study highlights a direct link between oxidative stress and diabetic complications through the measurement of a number of markers of oxidative stress. ere are multiple sources of oxidative stress in diabetes, including nonenzymatic, enzymatic and mitochondrial pathways. Direct evidence of oxidative stress in diabetes is based on studies that focused on the measurement CRP: high sensitive C-reactive protein n; NT-proBNP: of oxidative stress markers such as plasma and urinary F2-isoprostane [23] . In this study, levels of 15-F2t-IsoP, a biologically active product of lipid peroxidation, were signi cantly higher in diabetic patients than in the control group. On the other hand, there was no signi cant di erence between diabetics with and without complications. Also, a positive correlation was determined between 15-F2t-IsoP and both fasting glucose and HbA1c in the diabetic group with complications. Similarly, there was a positive correlation between 15-F2t-IsoP and fasting glucose in all diabetic patients. 15-F2t-IsoP in the diabetic group with complications, not well-regulated with medication, would suggest an interaction between hyperglycemia and glucose variability with respect to the formation of reactive oxygen species. Increased levels of F2-isoprostanes can be found in the plasma or urine of patients a ected by several diseases, including diabetes, and are used as indicators of lipid peroxidation [24] [25] [26] [27] [28] . Increased isoprostane levels in diabetic patients with chronic heart failure have been shown to be correlated with antioxidant status and disease severity [29] . Consequently, modulation of enzymes as superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase in target organs such as heart and kidney, prone to diabetic complications, may be bene cial in the prevention and management of heart and kidney failure [23] . Although our results indicate a close relation between hyperglycemia and lipid peroxidation, there are no di erences in HEL between all groups, which is the earliest marker of lipid peroxidation. While many previous studies report an increase of lipid peroxidation products in diabetic patients [30] , several report no signi cant increase [31] . Extensive HEL staining was observed in db/db mice in experimental study [32, 4] . Urinary excretion of Nε-(hexanoyl) has also been shown to be signi cantly higher in patients with diabetes than in control subjects [3] . F2-isoprostanes increase in both type 1 and type 2 diabetes, according to a study by Gopaul et al. [33] . ey reported that 8-iso-PGF2α (a major F2-isoprostane) was three times higher in Tabak et al. Diabetes mellitus and oxidative stress type 2 diabetics than in healthy people. Vascular complications represent the major cause of morbidity and mortality in diabetic patients. Since oxidative stress plays a key role in diabetic complications, isoprostanes are biologically active products of arachidonic acid metabolism that is related to vascular diseases [34] .
ere is extensive experimental evidence that oxidative damage permanently occurs in lipids of cellular membranes, proteins and DNA. In nuclear and mitochondrial DNA, 8-OHdG or 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) is one of the predominant forms of free radical-induced oxidative lesions and has therefore been widely used as a biomarker for oxidative stress and disease [35] . Kakimoto et al. [12] have also shown that the levels of 8-OHdG are increased in kidney tissues of streptozotocin-induced diabetic rats. In the present study, we showed that diabetic patients, especially patients with complications, demonstrated oxidative DNA damage. 8-OHdG levels in urine and mononuclear cells of type 2 diabetic patients with either retinopathy or nephropathy were much higher than those in patients without complications [36] . Diabetic patients have more severe oxidative DNA damage than normal subjects. Levels of oxidative DNA damage are increased in diabetic patients, suggesting that increased oxidative stress may be associated with the progression of diabetes, especially in diabetic patients with nephropathy [37] . In combination with previously published results, these results suggest that serum 8-OHdG is a potentially useful biomarker for evaluating the severity of complications in patients with DM.
AOPP is produced during oxidative stress. is procedure is carried out by myeloperoxidase in active neutrophils with the e ects of hypochloric acid and chloramines. ese products are identi ed as proteins that have crosswise conjunctions with dytrosine. Additionally, these are reliable markers to measure oxidative modi cation of proteins. Biochemical characterization of AOPP in plasma reveals that both the high-and lowmolecular-weight AOPP peaks contain oxidized albumin in aggregate-forming or monomeric form [38] . In the present study, the occurrence of protein oxidation in plasma of diabetic patients was also con rmed by a novel marker (AOPP) that provides information on the degree of oxidative damage to proteins. Moreover, patients with diabetic complications also had signi cantly higher AOPP levels than diabetic patients without vascular complications. Pan et al. [39] also showed that serum AOPP and protein carbonyl were signi cantly higher in type 2 DM compared with normal subjects. Diabetic patients with retinopathy had signi cantly higher AOPP and protein carbonyl compared with diabetic patients without retinopathy [39] .
ese data are in agreement with those of other authors [39] [40] [41] [42] . ese ndings suggest that oxidative protein damage begins in early stages of diabetes and continues to increase as the disease progresses and that AOPP is also a valid biomarker for assessing oxidative stress in diabetes. PON1 is an enzyme located on serum HDL that has been observed in experiments. Its function is to decrease the accumulation of lipid peroxides on LDL [43, 44] . In this study, 15-F2t-IsoP and AOPP levels were shown to increased signicantly in diabetes, while PON1 activity decreased. ese data con rm the previous observations [45] [46] [47] [48] [49] of low PON activity in type 2 diabetes. DM is accompanied by the development of oxidative protein damage as evaluated by an increase in the circulating oxidized proteins [40, 42] . is change could be related to an increased risk of endothelial damage. Indeed, these biochemical modi cations could a ect PON1 activity and, as a result, lead to an increased susceptibility of plasma proteins to protein oxidation in diabetic individuals. erefore, the reduction of the PON1 activity, as well as its antioxidant activity, could negatively a ect the atheroprotective properties of plasma proteins in DM. Paraoxonase activities are a ected by PON1 genetic variability in Turkish NIDDM patients and controls. PON1 polymorphisms and low PON activity levels were suggested as an independent risk factor for CHD in diabetic patients [47] . ere is evidence of a possible relationship between increased plasma protein oxidation parameters and decreased PON1 activity. Inactivation of PON1 itself may lead to a predisposition to atherosclerosis as well as increased markers of oxidative stress. It would be interesting to clarify whether the decrease in PON1 activity occurs selectively in preference to a range in other redox-sensitive enzymes with thiols in their active site, or there is a general diminution of enzyme activity.
Results of the present study showed that there were severe lipid peroxidation and protein oxidation, and DNA oxidative damage in patients exhibiting complications due to diabetes mellitus. ough the oxidative stress plays a role in the development of diabetic complications and acute e ects of hyperglycemia may be counterbalanced by antioxidants, further investigation is needed in order to con rm the relationship between these phenomena.
